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A B S T R A C T
Amphioctopus neglectus (Family: Octopodidae) is recognised as culinary delicacy in many cultures and a common
sea food item on the Mediterranean and Asian coasts. Bioassay-directed fractionation of ethyl acetate/methanol
extract of A. neglectus ensued in the characterisation of four previously undescribed macrocyclic lactones (1-4).
These compounds exhibited potential radical-scavenging capacities (IC50 0.95–1.73mM) along with anti-hy-
pertensive activities (IC50 1.12–2.34mM) against angiotensin converting enzyme (ACE). The optimum binding
affinity of compound 2 (−9.84 kcal mol−1) bearing furo[1,4,8]trioxacyclohexadecine-12,19-dione moiety with
ACE, along with its permissible hydrophobic-hydrophilic balance, manifested towards its greater anti-hy-
pertensive activity compared to other analogues. The compound 2, with lesser values of the inhibitory constant
(Ki= 1.0mM) towards ACE, was found to bind more effectively to the enzyme in a non-competitive manner, and
could describe the greater inhibitory ramifications than those displayed by other compounds (Ki> 1.1mM). The
ex-vivo studies revealed that compound 2 imparted protective effects against angiotensin-II induced cardiac
hypertrophy at 25 μg mL−1 on H9C2 cell lines, wherein about 34 percent decrease in cell area with increase in
viability could be attributed to anti-hypertrophic effects of the compound administrated. These results confirmed
that the protective effect of the isolated macrocyclic lactones is mediated by enhancement of anti-oxidant de-
fense systems, which subsequently attenuates the hypertensive related disorders.
1. Introduction
The marine cephalopods belonging to family Octopodidae are
gaining commercial significance due to their high nutritive values and
various pharmacological potentials [1]. The marine octopuses (Family:
Octopodidae) are ubiquitous throughout the oceans, and have been
recognised as high-value health food for human consumption [2].
Globally octopus landing and consumption have increased 6.7 percent
in 2016 compared with 2014. The increase was registered in major
suppliers (Morocco, Mauritania and Mexico), and Japan experienced a
significant increase in imports of octopus [2]. Among various cepha-
lopods, Amphioctopus neglectus (neglected ocellate octopus, Family:
Octopodidae) is widely distributed in marine waters, and has been
considered as culinary delicacy at various parts of world. Previous re-
ports of literature recognised the anti-oxidant and anti-hypertensive
activities of crude extract [3,4] and bioactive compounds from the
edible tissues of the genus [5]. The octopus as a food is a remedy to
fight diseases, such as atherosclerosis, cardiac arrhythmia, eczema,
macular degeneration, rickets etc., and is a source of taurine that helps
reducing cholesterol from blood vessels thereby preventing formation
of blood clots in body [6]. Angiotensin-I-converting enzyme (ACE-I) in
the rennin angiotensin aldosterone system (RAAS) displayed an im-
portant part in the modulation of blood pressure and cardiovascular
function, as it converts the inactive decapeptide angiotensin-I (Ag-I)
into the potent vasoconstricting octapeptide angiotensin-II (Ag-II),
which potentially narrows the opening of a blood vessel lumen and
increases vascular resistance. Additionally, Ag-II plays a pivotal role in
the release of aldosterone, from the adrenal cortex and subsequently
leads to hypertension. ACE is a multifunctional enzyme that also cata-
lyses the degradation of bradykinin, a vasoactive nonapeptide helpful in
arteriolar dilation and increased capillary permeability in the kallik-
rein-kinin system [7]. Hypertension is a metabolic disorder that is im-
plicated by a consistent increase in blood pressure, and has been con-
sidered as the critical threat for cardiovascular disease (CVD) all
through the world. Previous report of literature demonstrated that there
had been nearly 1 billion ailing individuals with CVD at the end of
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2000, and was anticipated to reach more than 1.5 billion during 2025
[8]. The presence of excess reactive oxygen species in biological sys-
tems was found to assume an essential part in the homeostasis of vas-
cular wall through disruptions in the biochemical pathway of RAAS,
and subsequently contribute towards the pathophysiology of hy-
pertension [9]. Thus, an increased presence of anti-oxidants was re-
cognised to be beneficial to combat hypertension and other related
ailments [10]. Inhibition of ACE-I has been thought to be a restorative
approach in the treatment of hypertension [7,11–13]. Currently, syn-
thetic anti-hypertensive medications are extensively used in clinical
treatment of hypertension, and prolonged intakes of these synthetic
analogues were reported to exhibit adverse effects [14]. Therefore, the
search for food-based anti-hypertensive inhibitors are of immense ap-
peal and functional food products could likely perform the necessity.
Marine-based functional food is attaining immense consideration in
nutraceutical industries due to their protective function against various
chronic diseases and availability [15,16].
The oxygenated macrocyclic lactones or ethers were found to be 10-
membered cyclic systems enclosing ester or ether functionalities, and
were recognised as important sources of nutraceuticals or medicines
with multiple bio-potentials [17]. These marine macrocyclic lactones
were previously reported from invertebrates [18], sponges [19] and
algae [20]. The bioactive reaction centers of commonly utilised anti-
oxidant agent, α-tocopherol and anti-hypertensive agent captopril were
found to possess heterocyclic functionalities. However, the structure-
activity analyses of captopril revealed that its lesser lipophilic value
(manifested as logarithm of octanol-water partition coefficient, log Pow)
(log Pow 0.24) than ideal (2–5) might result in poor bioavailability [21].
Likewise, the greater lipophilic (log Pow 9.9) and steric factors of α-
tocopherol might diminish its bioavailability [22]. Therefore, search for
oxygenated macrocyclic ring framework as the basic anti-hypertensive
center with higher polarisability and optimum lipophilicity (log Pow
2–5) descriptors could be vital for greater bioactivity. Molluscs have
been extensively consumed as the culinary delicacies, and were re-
ported to possess bioactive metabolites categorised under various
classes of chemistries [23,24], such as macrocyclic ethers, oxygenated
heterocyclics, polysaccharides, macrocyclic lactones etc., with pro-
mising pharmacological functions [16,25].
As a continuing program to investigate bioactive oxygenated mac-
rocyclic lactone analogues from the economically important seafood
species, ethyl acetate-methanol (EA-MeOH) extract of A. neglectus was
partitioned by sequential chromatographic fractionation. In view of
this, we have described the isolation and identification of four macro-
cyclic lactone derivatives for the first time. These were characterised
using Fourier transform infrared (FTIR), nuclear magnetic resonance
(NMR), and mass spectroscopic analyses. The macrocyclic lactone
analogues identified in the present study were assessed for anti-oxidant
activities by selective radical scavenging assessments, whereas their
inhibitory properties against ACE enzyme, which is a component of
renin-angiotensin framework to develop the pathophysiology of hy-
pertension, determined their anti-hypertensive potentials. Structure-
bioactivity interrelationships of macrocyclic lactones were examined by
different physico-chemical characteristics and modes of inhibition
against hypertensive enzymes by kinetic analyses and molecular
docking simulation studies. Ameliorating potentials of these com-
pounds against hypertrophy prompted by Ag-II in H9C2 cells and their
sequel on oxidant-induced stress were also determined.
2. Materials and methods
2.1. Samples and preparation of solvent extracts
The specimens of A. neglectus (5 kg) were collected afresh from the
landing centre of Arabian-Sea located at Lat 8°48′ N, Long 78°9′ E; Lat
9°14′ N, Long 79°14′E, through the Southwestern coast of the Indian
subcontinent. The species was cleaned to remove debris and other dirt
remains. The ink-gland was carefully separated, and the edible part
homogenated. The ground samples were lyophilised by using a freeze-
drier (Labogene Scanvac Cool Safe, Denmark) yielding the freeze-dried
powder (1500 g, yield 30%). The lyophilised powder was extracted in
EA-MeOH (1:1, v/v, 1000ml × 3) by way of sonication (8 h) under an
inert atmosphere. The organic fraction was filtered by anhydrous so-
dium sulfate (Na2SO4) taken after by vacuum evaporation on a rota-
vapour (50 °C; Heidolf, Germany) to afford the crude extract of A. ne-
glectus (68 g, yield 4.5% on dry weight basis).
2.2. Chromatographic partitioning and spectroscopic identification
The crude EA-MeOH extract of A. neglectus (68 g) was sequentially
partitioned by column chromatographic fractionation. The crude was
homogenated with coarse silica (60–120 mesh, 5 g) and packed into the
open glass column (100 cm×4 cm) charged with silica gel (60–120
mesh, 85 g). The column was primarily eluted with n-hexane followed
by EA and MeOH, to acquire a total of 5 column fractions (AM1 through
AM5). The bioactive properties of AM1-5 were examined, and two of
them (AM3 and AM4) were chosen for additional fractionations owing
to their higher anti-hypertensive and anti-oxidant properties against
ACE-I (IC50< 1mgmL−1) contrasted to others (IC50> 1.25mgmL−1)
(Table S1). The fraction AM3 (18 g; 26.47%) was fractionated by va-
cuum-liquid chromatographic experiment on a column (45 cm×3 cm)
charged with fine silica (230–400 mesh) utilising increasing gradient of
n-hexane/chloroform (CHCl3)/MeOH yielding 24 fractions (25ml each)
that were combined to 12 groups (AM3-1-AM3-12) after thin layer
chromatographic (TLC) (CHCl3:MeOH, 7:3 v/v) analysis. The fraction
AM3-12 (25% MeOH:CHCl3; 3256mg; 18.08%) registered greater
bioactive properties against 2,2-diphenyl-1-picrylhydrazyl (DPPH) and
ACE-I (IC50< 0.8mgmL−1) than other fractions, and thus, was chosen
for additional fractionation. The fraction AM3-12 was purified using
reverse-phase preparative high-pressure liquid chromatography (RP-
HPLC, C18-1.4 cm×25 cm, 5 μm) with acetonitrile (MeCN)/MeOH
(80:20 v/v; 10ml min−1) to afford compounds 1 (Rt 18.36min, 84mg),
2 (Rt 19.74min, 150mg), and 3 (Rt 25.16, 75mg), which were found to
be homogeneous in TLC (EA/n-hexane, 20:80 v/v) and RP-HPLC
(MeOH: MeCN, 70:30 v/v).
The fraction, AM4 (16.6 g; 23.5%) was chromatographically parti-
tioned on a glass column (90 cm×4 cm), packed with fine silica gel
(230–400 meshed, 32 g) before being fractionated by a solvent gradient
of CHCl3/MeOH to afford ten fractions, named as AM4/1 through AM4/
10 (each of 12mL). These sub-fractions were combined to six sub-
fractions (AM4-1-AM4-6) after TLC analysis (CHCl3: MeOH, 8.5:1.5 v/v).
The sub-fraction AM4-5 (1321mg) was found to possess greater bioac-
tivities, and was purified using preparative HPLC (C18-1.4 cm×25 cm,
5 μm) with MeCN/MeOH (30:70, v/v; 10mL/min) to yield compound 4
(Rt 28.116min, 62mg) to homogeneity (RP-C18 HPLC, MeOH: MeCN
2:3 v/v: 14.28min).
2.2.1. 5-((Z)-Hex-12-enyloxy)-7-hydroxy-5-methyl-1, 4-dioxecan-10-one
(1)
Yellowish oil; UV (Varian Cary UV–vis spectrophotometer) λmax
MeOH (log ε 2.55): 203 nm; [α]26D -18.2° (CHCl3, c0.015); TLC (silica GF-
254; EA/n-hexane, 1:4 v/v) Rf: 0.43; Rt (RP-C18 HPLC, Shimadzu,
Japan; C18 25 cm×0.46 cm, 5 μm; MeOH: MeCN, 7:3 v/v): 10.278min
(Fig. S1); 1H NMR (proton), 13C NMR (carbon), heteronuclear multiple-
bond correlation spectroscopy (HMBC), heteronuclear single quantum
coherence (HSQC), proton correlation spectroscopy (1H-1H COSY), and
nuclear overhauser effect spectroscopy (NOESY) (Fig. S2-S8, Table 1);
high-resolution electron-impact mass spectrometry (HREIMS): found
m/z 300.1942 [M]+, cal. for C16H28O5 300.1937 (Δ= 1.7 ppm) (Fig.
S9-S10); infrared (IR; stretching ν, bending δ, rocking ρ) (cm−1): 3453
(br, OeHν), 2926, 2855 (CeHν), 1723 (C=Oν), 1630 (C=Cν), 1469,
1089 (CeHδ), 1285 (CeHρ), 1045 (CeOeCν), 967 (=C-Hδ), 799 (CeHδ)
(Fig. S11).
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Table 1
NMR spectroscopic data of compounds 1-4 in CDCl3†.
C. No. 13C 1H (int.,mult.,J in Hz)‡ 1H-1H COSY HMBC C. No. 13C 1H (int.,mult.,J in Hz)‡ 1H-1H COSY HMBC
1 – – – – 1 – – – –
2 59.09 4.30(2H,t) H-3 C-3,10 2 59.25 4.15(2H,t) H-3 C-19
3 66.04 3.68(2H,t) – C-5 3 66.06 3.51(2H,t) – C-5
4 – – – – 4 – – – –
5 90.68 – – – 5 53.10 3.10(1Hα,m) H-6,H-9 C-2,3,7,9,10
6 24.59 1.60(2H,d) H-7 C-5,8,9 6 25.06 1.89(2H,m) H-7 –
7 53.32 3.33(1Hα,p) H-8 – 7 63.52 3.88(2H,t) – –
8 29.39 2.01(2H,m) H-9 C-10 8 – – – –
9 33.46 2.35(2H,t) – C-6,7,8,10 9 70.55 5.11(1Hβ,t) H-10 C-6
10 173.63 – – – 10 62.23 4.28(1H,d) – C-12
11 63.53 4.03(2H,d) H-12 C-5 4.05(1H,d) – –
12 127.14 5.38(1H,td,3.2,5.4 Hz) – – 11 – – – –
13 129.54 5.27(1H,td,3.2,6.2 Hz) H-14 – 12 172.30 – – –
14 28.80 2.06(2H,m) H-15 C-12,13 13 33.51 2.19(2H,d) H-14 C-12
15 29.07 1.35(2H,m) – C-14,16,17 14 25.21 1.45(1Hβ,m) H-14a,H-15 C-12,13,14a
16 22.07 1.33(2H,m) H-17 – 14a 29.39 2.22(2H,t) H-14b C-15
17 13.04 0.92(3H,t) – C-15,16 14b 128.92 5.27(1H,dt,5.2,6.0 Hz) – C-14,14a,14d
18 31.67 1.31(3H,s) – C-6 14c 131.49 5.25(1H,dt,5.1,6.4 Hz) H-14d C-14b,14d,14e
– – – – – 14d 20.12 1.94(2H,m) H-14e C-14b,14c,14e
– – – – – 14e 13.08 0.98(3H,t) – C-14d
– – – – – 15 22.33 2.26(2H,d) – C-14,16a
– – – – – 16 126.77 – – –
– – – – – 16a 33.63 2.00(2H,t) H-16b C-16,17
– – – – – 16b 31.67 1.37(2H,m) H-16c C-16a,16c
– – – – – 16c 13.31 0.90(3H,t) – –
– – – – – 17 127.68 5.24(1Hα,t,4.9 Hz) H-18 C-18
– – – – – 18 24.60 2.72(2H,d) – C-17,19
– – – – – 19 173.79 – – –
C. No. 13C 1H (int.,mult.,J in Hz)b 1H-1H COSY HMBC C. No. 13C 1H (int.,mult.,J in Hz)b 1H-1H COSY HMBC
1 – – – – 1 – – – –
2 172.78 – – – 2 172.55 – – –
3 24.62 2.89(2H,d) H-4 C-2,4 3 33.54 2.43(2H,d) H-4 C-2,4,5,19
4 131.43 5.42(1H,q,5.1Hz) – C-2,3,5 4 25.22 2.11(1Hβ,m) H-5,H-19 C-2,6,20,22
5 127.83 5.41(1H,t,5.4Hz) H-6 – 5 20.14 1.96(2H,t) H-6 C-2,6
6 33.52 2.35(1Hβ,t) H-7 C-5,7,7a,10, 11 6 129.00 5.37(1H,q,2.9 Hz) – C-4
7 25.21 2.06(1Hα,t) H-7a,H-8 C-5,8,9 7 127.67 5.39(1H,q,3.8 Hz) H-8 –
7a 22.35 1.38(2H,m) H-7b C-6 8 24.62 2.88(2H,d) – C-7,9
7b 13.07 0.92(3H,t) – C-7a 9 131.43 – – –
8 127.71 5.40(1H,t,7.3Hz) – C-7a 10 128.09 5.41(1H,t,2.3Hz) H-11 –
9 126.80 5.38(1H,t,5.2Hz) H-10 C-8 11 31.69 2.34(2H,t) H-12 C-9,12
10 31.69 2.85(1Hβ,t) H-15 C-8,11 12 53.38 3.33(1Hα,p) H-13 C-14
11 92.06 – – – 13 25.20 2.04(2H,d) – C-12,14
12 – – – – 14 70.51 – – –
13 66.07 3.66(2H,t) H-14 C-11,14 15 – – – –
14 59.04 4.28(2H,t) – C-2 16 65.96 3.73(2H,d) H-17 C-14,17
15 33.78 2.43(2H,d) – C-9,10,16 17 59.31 4.34(1Hα,d) –
(continued on next page)
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2.2.2. 14-((Z)-Pent-14b-en-14a-yl)-16-propyl-octahydro-furo[1,4,8]
trioxacyclohexadecine-12,19-dione (2)
Yellowish oil; UV λmax MeOH (log ε 2.17): 202 nm; [α]26D -20.1°
(CHCl3, c0.012); TLC (silica GF-254; EA/n-hexane, 1:4 v/v) Rf: 0.54; Rt
(RP-C18 HPLC; MeOH: MeCN, 7:3 v/v): 11.05min (Fig. S12); 1H NMR,
13C NMR, HMBC, HSQC, 1H-1H COSY, and NOESY (Fig. S13-S19,
Table 1); HREIMS: found m/z 408.2516 [M]+, cal. for C23H33O6
408.2512 (Δ=1.0 ppm) (Fig. S20-S21); IR (cm−1): 2925, 2854
(CeHν), 1635 (C]Oν), 1458 (CeHδ), 1399, 1321, 1261 (C-Hρ), 1090,
1058 (CeOeCν), 980, 667 (]CeHδ) (Fig. S22).
2.2.3. 16-(18-Methoxyethyl)butyl-16-((4Z)-7-ethyl-octahydro-11-
hydroxy-2-oxobenzo[1,12]dioxecin-10-yl)acetate (3)
Yellow oily; UV λmax MeOH (log ε 2.76): 205 nm; [α]26D -18.6° (CHCl3,
c0.015); TLC (silica GF-254; EA/n-hexane, 1:4 v/v) Rf: 0.62; Rt (RP-C18
HPLC; MeOH: MeCN, 1:4 v/v): 13.025min (Fig. S23); 1H NMR, 13C
NMR, HMBC, HSQC, 1H-1H COSY, and NOESY (Fig. S24-S30, Table 1);
HREIMS: found m/z 424.2466 [M]+, cal. for C23H36O7 424.2461
(Δ=1.2 ppm) (Fig. S31-S32); IR (cm−1): 3453 (br, OeHν), 2926, 2855
(CeHν), 1730 (C]Oν), 1629 (C]Cν), 1470 (CeHδ), 1323, 1227
(CeHρ), 1088 (CeOeCν), 971 (]CeHδ) (Fig. S33).
2.2.4. (Z)-12-Hydroxy-14-methyl-4-(pentan-19-yl)-octahydro-benzo
[1,15]dioxacyclotridecin-2-one (4)
Brown oily; UV λmax MeOH (log ε 2.76): 205 nm; [α]26D -19.4° (CHCl3,
c0.016); TLC (silica GF-254; EA/n-hexane, 1:4 v/v) Rf: 0.71; Rt (RP-C18
HPLC, MeOH: MeCN, 2:3 v/v): 14.209min (Fig. S34); 1H NMR, 13C
NMR, HMBC, HSQC, 1H-1H COSY, and NOESY (Fig. S35-S41, Table 1);
HREIMS: found m/z 350.2462 [M]+, cal. for C21H34O4 350.2457
(Δ=1.4 ppm) (Fig. S42-S43); IR (cm−1): 3439 (br, OeHν), 2925, 2855
(CeHν), 1736 (C]Oν), 1624 (C]Cν), 1466 (CeHδ), 1386, 1323, 1257
(CeHρ), 1055 (CeOeCν), 804 (]CeHδ) (Fig. S44).
2.3. Anti-oxidant, anti-hypertensive assays and structure-bioactivity
interrelationship analysis
2.3.1. Anti-oxidant assays
The anti-oxidant properties of the studied macrocyclic lactones (1-
4) isolated from A. neglectus were resolved by in vitro DPPH and ABTS+
(2, 2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) radical-
scavenging analyses [26]. The percentage inhibition (%) was calculated
as follows: [(ACL-ASL)/ACL) * 100], where ACL and ASL represented the
absorbance of control and sample, respectively. Median inhibitory
concentration of the compounds were calculated [27], and the results
were showed as IC50 (mM), the concentration at that they inhibit the
free-radical activities to their half.
2.3.2. Anti-hypertensive assay
The studied compounds, 1-4 were assayed for their potential to
inhibit the ACE-I activity. ACE inhibition activity was manifested as
reaction rate (δA min−1), and was calculated as, ACE inhibition (%) =
[(δA min−1 (blank) - δA min−1 (sample))/ δA min−1 (blank)]× 100.
The concentration of compounds that blocked ACE activity to its half of
the original activity (IC50) was calculated [13].
2.3.3. Structure-bioactivity interrelationship analysis
The molecular physico-chemical characteristics, such as hydro-
phobic (logarithmic value of octanol/water partition coefficient, log
Pow), polar (polarisability Pl and topological polar surface area tPSA),
and bulk (Pr parachor, MR molar refractivity, and MV molar volume)
parameters were used to study the structure-bioactivity interrelation-
ship analysis of the of the macrocyclic lactones [28]. These parameters
were deduced by ACD ChemSketch (version 12; ACD Inc., Canada) and
ChemDraw Ultra (version 12.0; Cambridge Soft Corporation, MA, USA)
programs.
2.4. Kinetics of ACE inhibition
Kinetic analyses by Dixon and Lineweaver-Burk plots were used to
assess mechanism to inhibit ACE by the macrocyclic lactone analogues
(1–4). The ACE-I inhibition was surveiled at different concentrations
(0.0625, 0.125, 0.25 and 0.5 mM) of substrate N-[3-(2-furyl)acryloyl]-L-
phenylalanyl-glycyl-glycine (FAPGG), in presence and absence of the
compounds, in Lineweaver-Burk double-reciprocal plots. The com-
pounds were used in different concentrations, and the inhibitory ac-
tivities were expressed in mM. The kinetic parameters, such as max-
imum rate of ACE-catalysed reaction (Vmax) and Michaelis constant of
ACE (Km) were determined as intercepts in Y and X-axis of Lineweaver-
Burk double-reciprocal plot [29]. The inhibition constant (Ki) was cal-
culated by elucidation of Dixon plots (single reciprocal plot), which
Table 1 (continued)
C. No. 13C 1H (int.,mult.,J in Hz)b 1H-1H COSY HMBC C. No. 13C 1H (int.,mult.,J in Hz)b 1H-1H COSY HMBC
16 173.53 – – – 4.05(1Hβ,d) C-2,14
17 63.95 4.02(2H,d) H-18 C-16,19 18 22.35 1.31(3H,s) – C-14
18 20.13 2.11(1Hα,m) H-18a,H-19 C-20 19 39.00 1.62(2H,m) H-20,22 C-20,22
18a 29.41 1.36(2H,m) H-18b C-18 20 29.01 1.33(2H,m) H-21 C-21
18b 13.31 1.00(3H,t) – C-18,18a 21 13.33 0.99(3H,t) – –
19 25.19 1.60(1Hβ,m) H-20 C-18b 22 29.41 1.36(2H,m) H-23 C-23
1.56(1Hα,m) 23 13.09 0.92(3H,t) – –
20 68.88 3.62(2H,t) – C-21 – – – – –
21 53.32 3.24(3H,s) – C-20 – – – – –
† NMR spectra were recorded using a Bruker AVANCE III 500MHz (AV 500) spectrometer (Bruker, Karlsruhe, Germany) in CDCl3 as aprotic solvent at ambient
temperature with TMS as the internal standard (δ 0 pm).
‡ Values in ppm, multiplicity and coupling constants (J=Hz) were indicated in parentheses. Multiplicities were allocated by 135DEPT NMR spectrum.
The assignments were made with the aid of the COSY, HSQC, HMBC and NOESY experiments. The stereo-chemical orientations in the structures were represented by
wedge-faced and dash-faced bonds based on NOESY spectra.
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were set up by representing 1/V against substrate (inhibitor) con-
centrations.
2.5. In silico molecular docking analysis
Molecular docking analyses of the studied macrocyclic lactones
were accomplished by using the docking software (Autodock 4, version
1.5.6), to evaluate the conformation of ligand-protein framework. The
titled compounds were built with Chemsketch software (version 3.5)
before being saved as MDL-molfiles, which were transformed to PDB
format with Open Babel GUI (version 2.4.1). The crystal structure of
ACE-I (PDB: 1UZE; resolution 2.0 Å) [30] was recovered from protein
databank (dedicated website, www.pdb.org), wherein the water mole-
cules were eliminated from target enzymes, and the structure of protein
was energetically diminished (Swiss-PdbViewer SPDBV v4.1.0). The
diminished protein was accounted for molecular docking analysis to
assess their feasible binding manner between the ACE-I active sites,
calculate the energy of complex and binding affinity. The cofactors,
ligands, and protein-bound water were removed while carrying out the
docking analysis. The target enzyme was examined for partial atoms
and polar hydrogens, where Kollman charges were designated. Torsion
bonds of the studied macrocyclic lactones were chosen and defined,
wherein the 3D-grid box was generated by Auto-Grid calculation to
assess the coupling energies on the ACE-coordinates. Grid map set va-
lues for docking of ACE-I were selected as x=39.979, y= 37.622,
z= 50.808 (56 Å×58 Å×58 Å) points. The running of the docking
calculation was utilised using Cygwin-1/Cygwin-2, and root-mean-
square deviation was studied for assessing lowest energy of binding. A
chimer programming (University of California, San Francisco-UCSF)
was utilized for representation and investigation of results to perceive
H-bonding connections between designated macrocyclic lactones and
target ACE-I.
2.6. Ex-vivo study to inhibit angiotensin-II (Ag-II) induced cardiac
hypertrophy on H9C2 cells
Ex-vivo studies were performed to demonstrate the inhibition of
angiotensin-II (Ag-II) induced cardiac hypertrophy on H9C2 cells.
Cardiomyoblast (H9C2) cell line was obtained from the NCCS (National
Centre for Cell Sciences) of Pune, India, and was preserved in
Dulbecco’s Modified Eagles’ Medium (DMEM) (Sigma Aldrich, USA).
The H9C2 cell lines cultured with DMEM, were added with fetal bovine
serum (10% FBS), amino acid L-glutamine, sodium hydrogen carbonate
along with a solution containing the antibiotics streptomycin (100 μg
mL−1), penicillin (100 U mL−1), and amphoteracin-B (2.5 μg mL−1)
before being maintained in a CO2 incubator (NBS Eppendorf, Germany)
retained at a temperature of 37 °C and 5% relative humidity. The
growth of cells was assessed by directly examining the cells with an
inverted phase-contrast microscope (20 × magnification) before being
analysed by MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenylte-
trazolium bromide] assay. The inhibitory potential of the compound
attenuating cardiac hypertrophy on H9C2 cell lines by Ag-II was ana-
lysed by morphological changes using inverted phase contrast tissue
culture microscope (20 × magnification) by crystal violet staining
method followed by image analysis using Image J analysis software.
2.6.1. Cell seeding in 96-well plate and preparation of compound stock
Two-day old coalescent cell-monolayer was trypsinised before being
dispersed in the cell growth medium (10%). The suspension of cells
(100 μL, 5× 104 cells well−1) was implanted in 96-well plate and
maintained in a CO2 incubator (NBS Eppendorf, Germany) retained at a
temperature of 37 °C and 5% relative humidity. The selected compound
(1mg) was dissolved in DMEM (1mL) with a cyclo-mixer before being
clarified with a syringe filter (Millipore, USA, 0.22 μ) to ensure the
sterility.
2.6.2. Cytotoxicity evaluation by direct microscopic observation
After acquiring adequate growth of the H9C2 cell lines, angiotensin
(100 μM) was added to induce toxicity and the mixture was incubated
for 1 h. The studied compound (in DMEM, 5%) were serially diluted
(5×) by two-times dilution (100 μg, 50 μg, 25 μg, 12.5 μg and 6.25 μg in
500 μl of DMEM). Each concentration (100 μL) was added to the wells
before being incubated (37 °C, 5% RH) for 24 h. Entire plate was ob-
served after the incubation period with a phase-contrast (inverted)
microscope at 20× magnification (CKX-41, Olympus, USA), wherein
any perceivable alteration in the cellular morphology, for example,
shrinking or rounding, vacuolisation and granulation of cell cytoplasm
were contemplated as markers of cytotoxicity. The surface area of cells
from each group (40 to 50 cells group−1) was determined and com-
pared with the control group (untreated H9C2 cell lines) using Image J
analysis software.
2.6.3. MTT-based cytotoxicity appraisal
MTT (15mg, Sigma, M-5655) was added with the phosphate buffer
saline (PBS, 3mL) till thoroughly dissolved before being filter-sterilised
and incubated for 24 h. The samples in wells were separated, MTT so-
lution (30 μL) was added to the plate wells, and the contents were in-
cubated (37 °C, 5% RH) for 4 h. Following the incubation, the clear
upper layer was removed, and dimethyl sulfoxide (100 μL) was added in
the wells with gentle mixing in order to dissolve the crystals of N'-
amino-N-iminomethanimidamide (formazan). The absorbance values
were analysed (at 540 nm), and the growth inhibition (as percent) was
calculated as [ODsamples×100)/ODcontrol].
2.7. Statistical analysis
The statistical software SPSS (Statistical Program for Social
Sciences, version 13.0; USA) was utilised to ascertain the significant
difference by using ANOVA (one way analysis of variance) between
means. The results were presented as the mean of replicate experiments
with a 5% level of significance (p < 0.05).
3. Results and discussion
3.1. General
The marine cephalopods belonging to family Octopodidae represent
a considerable share in the fishery sector, and were described to hold
structurally different bioactive metabolites with respect to various
pharmacological activities [4]. The present study deals with isolation of
bioactive oxygenated macrocyclic lactone metabolites from EA-MeOH
extract of A. neglectus using extensive spectroscopic techniques. The
bioactive properties of isolated macrocyclic lactone analogues with
respect to their anti-oxidant and anti-hypertensive activities using in
vitro and ex vivo pharmacological models were assessed.
3.2. Chromatographic fractionation and structural characterisation of
macrocyclic lactones from A. neglectus
The EA-MeOH extract of A. neglectus was firstly fractionated to five
key sub-fractions (AM1-AM5), and among which AM3 and AM4 dis-
played significantly greater recovery (24–26 %) than AM1, AM2 and
AM5 (< 20%). The sub-fractions, AM3 and AM4 also exhibited higher
anti-oxidant (IC50 DPPH scavenging 0.8–1.12mgmL−1; IC50 ABTS+ scavenging
1.03–1.06mgmL−1) and anti-hypertensive (IC50 ACE-I inhibitory
1.06–1.10mgmL−1) properties than those displayed by AM1, AM2 and
AM5 (IC50> 1.25mgmL−1) (Table S1). Therefore, AM3 and AM4 were
selected for downstream chromatographic purification to obtain four
macrocyclic lactone derivatives (1-4). The structures of the studied
compounds were elucidated by inclusive spectroscopic techniques
(Fig. 1).
The 10-membered cyclic lactone derivative, 5-((Z)-hex-12-enyloxy)-
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7-hydroxy-5-methyl-1,4-dioxecan-10-one (1), with molecular formula
C16H28O5 and molecular ion at m/z 300 (HRESIMS m/z: 300.1942
[M]+, cal. 300.1937) established the existence of three grades of un-
saturations corresponding to two double bonds and one cyclic system.
The compound 1 was deduced to enclose a hydroxyl attached 10-
membered cyclic lactone bonded to hexenyloxy side chain at C-5 that
was attributed by detailed HMBC and 1H-1H COSY assignments. The
compound recorded chemical shift signals for two methyls, three me-
thines, nine methylenes and two quaternary carbons that were assigned
by integrated 1H/13C NMR/DEPT. The 1H/13C NMR and DEPT signals
recognised characteristic functionalities of ester (δC 173.63), oxyge-
nated methylenes (δH 4.30/δC 59.09, δH 4.03/δC 63.53, δH 3.68/δC
66.04), oxygenated 4° carbon (δC 90.68), hydroxylated methine (δH
3.33, pentet/δC 53.32) and sp2 disubstituted alkene (δH 5.38/δC
127.14, δH 5.27/δC 129.54). The presence of hydroxyl moiety directly
bonded to methine at δC 53.32 was characterised by the non-appear-
ance of deuterated hydroxyl resonances in the 1H NMR by the deu-
teration of −OH proton. The 13C NMR spectrum exhibited a deshielded
singlet resonance for one carbon atom with δ 90.68 (C-5), which sug-
gested that the carbon atom was located between two oxygen atoms.
The macrocyclic lactone core enclosed two spin systems based on the
1H-1H COSY interactions, such as δ 4.30 (attributed to H-2)/3.68 (H-3)
(eOeCH2eCH2eOe) and δ 1.60 (H-6)/3.33 (H-7)/2.01 (H-8)/2.35 (H-
9). This was further confirmed by the long-range HMBCs from δ 4.30
(H-2) to δ 66.04 (C-3), 173.63 (C-10); δ 3.68 (H-3) to δ 66.04 (C-5); δ
1.60 (H-6) to δ 90.68 (C-5), 29.39 (C-8), 33.46 (C-9); δ 2.01 (H-8) to δ
173.63 (C-10); δ 2.35 (H-9) to δ 24.59 (C-6), 53.32 (C-7), 29.39 (C-8),
173.63 (C-10). The previous report of literature described a 10-mem-
bered macrolides that enclosed ester carbonyl, alkene and hydroxyls
[31], whereas the compound 1 enclosed one each of ester (C-10), hy-
droxyl (C-7) and ether groups. The COSY and HMBC correlations
among the methylene of ester (H-2) and oxygenated methylene (H-3)
proposed that these functionalities were aligned between oxygen
atoms, which were denoted as eC(]O)eOeCH2eCH2eOe, thus ether
linkage in the macrocyclic lactone was ascertained. The presence of
singlet methyl (δC 31.67 (C-18)/δH 1.31) at C-5 was attributed by the
HMBC interactions from δ 1.31 (H-18) to δ 24.59 (C-6), 90.68 (C-5).
The side chain attachment of hexenyloxy at C-5 exhibited COSY rela-
tions, such as δ 4.03 (H-11)/5.38 (H-12); δ 5.27 (H-13)/2.06 (H-14)/
1.35 (H-15) and δ 1.33 (H-16)/0.92 (H-17). The HMBCs from δ 2.06 (H-
14) to δ 127.14 (C-12), 129.54 (C-13); δ 1.35 (H-15) to δ 22.07 (C-16),
13.04 (C-17) and δ 0.92 (H-17) to δ 22.07 (C-16), 29.07 (C-15), which
further confirmed the assignments of hexenyloxy side chain. The lesser
coupling constants of 3.2, 5.4 and 3.2, 6.2 Hz concurred with the pro-
tons at H-12 and H-13, respectively demonstrated the cis-inclination of
alkenic group in the side chain. The attachment of (Z)-hex-12-enyloxy
side chain at C-5 was assigned by the HMBCs from δ 4.03 (H-11) to δ
90.68 (C-5). The compound 1 enclosed only one chiral centre at C-7 (δH
3.33) and its relative stereochemistry was deduced as α-disposed.
Therefore, the hydroxyl at C-7 was assigned to be β-oriented, which was
deduced as trans to the α-proton at δ 3.33. The IR spectrum of 1 showed
stretching bands at 3453 and 1723 cm−1 that confirmed the manifes-
tation of hydroxyl and lactone groups, respectively. Fragmentation of
molecular ion at m/z 300 resulted in the loss of methyl radical to yield
m/z 285. The latter underwent fragmentation to yield m/z 230, which
was on subsequent ethyl radical elimination yielded the fragment peaks
at m/z 203. The ion at m/z 203 on repeated elimination of methyl,
hydroxyl, methoxy radicals yielded m/z 82 that was congruous with the
pentenal ion radical, which on subsequent CH2•• elimination resulted in
the base peak m/z 58 corresponding to the propenol fragment.
A 16-membered cyclic bislactone derivative, 14-((Z)-pent-14b-en-
14a-yl)-16-propyl-octahydro-furo [1,4,8]trioxacyclohexadecine-12,19-
dione (2) was isolated by sequential chromatographic purification. Its
molecular formula was found to be C23H33O6 along with its molecular
ion m/z 408 (HRESIMS m/z: 408.2516 [M]+, cal. 408.2512) that pro-
posed the occurrences of six indices of unsaturation corresponding to
two rings and four double bonds. The compound enclosed a 16-mem-
bered macrocyclic bislactone fused to tetrahydrofuran ring at C-5 and
C-9. This bislactone ring skeleton was directly attached to the pentenyl
side chain at C-14 and propyl moiety at C-16 through detailed 1H-1H
COSY, HSQC and HMBC analyses. The 13C NMR in conjunction with
DEPT experiment signified the occurrence of 23 carbons, comprising 2
ester carbonyls at δ 172–173, four alkenes between δ 126–131, two
each of oxygenated methylenes (at δ 59 and 66) and methines (at δ 53
and 70). The characteristic functionalities corresponded to two oxyge-
nated methylene end of ester (δH 4.28, 4.05/δC 62.23; δH 4.15/δC
59.25); oxygenated methylene (δH 3.51/δC 66.06), oxygenated me-
thine (δH 3.10/δC 53.10; δH 5.11/δC 70.55), one each of trisubstituted
alkene (δC 126.77; δH 5.24/δC 127.68) and disubstituted alkene (δH
5.27/δC 128.92; δH 5.25/δC 131.49) were identified by detailed
1H/13C NMR and HSQC experiments. The 16-membered macrolides
with diesters and triesters along with 14-membered diesters were pre-
viously reported from marine organisms [32,33]. The basic skeleton of
bislactone ring fused to tetrahydro furan exhibiting four spin systems
Fig. 1. 1H-1H COSY (coloured bold-face bonds), selected HMBC (double-barbed arrows) and NOESY (double-sided coloured arrows) correlations of the compounds,
1-4 (A-D).
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was proposed on the basis of COSY correlations, which were found to be
δ 4.15 (H-2)/3.51 (H-3); δ 3.10 (H-5)/1.89(H-6)/3.88 (H-7) including δ
3.10 (H-5)/5.11 (H-9)/4.28, 4.05 (H-10); δ 2.19 (H-13)/1.45 (H-14)/
2.26 (H-15) and δ 5.24 (H-17)/2.72 (H-18). The presence of tetrahydro
furan fused bislactone was further supported by HMBC connections
from δ 4.15 (H-2) to δ 173.79 (C-19); δ 3.51 (H-3) to δ 53.10 (C-5); δ
3.10 (H-5) to δ 59.25 (C-2), 66.06 (C-3), 63.52 (C-7), 62.23 (62.23); δ
5.11 (H-9) to δ 25.06 (C-6); δ 4.28 (H-10) to δ 172.30 (C-12); δ 2.19 (H-
13) to δ 172.30 (C-12); δ 1.45 (H-14) to δ 172.30 (C-12) and δ 2.72 (H-
18) to δ 173.79 (C-19). The attachment of pentenyl side-chain at C-14
was proposed on the basis of COSYs, δ 1.45 (H-14)/2.22 (H-14a)/5.27
(H-14b) and δ 5.25 (H-14c)/1.94 (H-14d)/0.98 (H-14e), which were
enclosed in the cyclohexenyl ring. The HMBC cross-connections from δ
1.45 (H-14) to δ 29.39 (C-14a); δ 2.22 (H-14a) to δ 22.33 (C-15); δ 5.27
(H-14b) to δ 25.21 (C-14) attributed the pentenyl side chain attach-
ment. The occurrence of propyl chain was apparent from the COSY
interactions from H-16a to H-16b {δ 2.00 (H-16a)/1.37 (H-16b)/0.90
(H-16c)} and its attachment at C-16 was apparent by the HMBC in-
teractions from δ 2.26 (H-15) to δ 33.63 (C-16a) and δ 2.00 (H-16a) to δ
126.77 (C-16), 127.68 (C-17). The lesser coupling constants of protons
at H-14b (5.2, 6.0 Hz) and H-14c (5.1, 6.4 Hz) in the pentenyl side chain
suggested the cis-orientation of alkenic groups. The relative stereo-
chemical assignments of chiral protons at C-5, C-9 and C-14 were at-
tributed by NOE couplings. The NOE interactions between δ 5.11 (H-9)
and 1.45 (H-14) proposed their similar level of symmetry, and were
summarily designated as β-protons. Therefore, the pentenyl chain at C-
14 was trans aligned being converse to the β-inclined proton at δ 1.45.
The H-5 proton (δ 3.10) did not display any NOE cross-peaks with β-
protons, which showed their opposite plane of symmetry, and thus
assigned as α-oriented. The IR spectrum of 2 registered stretching ab-
sorptions at 2925-2854 and 1635 cm−1, which correspond to the al-
kanes and carbonyls, respectively. The fragment at m/z 339 eliminated
C2H3%, C2H5O% and CHO2% radicals to yield peaks at m/z 311, 241, and
199, respectively. The fragment at m/z 199 on sequential fragmenta-
tions resulted in the formation of m/z 74, which was congruous with
methoxyethenol (C3H6O2) fragment as base peak.
A 10-membered cyclic lactone derivative, 16-(18-methoxyethyl)
butyl 16-((4Z)-7-ethyl-octahydro-11-hydroxy-2-oxobenzo [1,12]diox-
ecin-10-yl) acetate (3), with molecular formula C23H36O7 and mole-
cular ion at m/z 424 (HRESIMS m/z: 424.2466 [M]+, cal. 424.2461)
was isolated from crude EA-MeOH extract of A. neglectus by chroma-
tographic separation. Six hydrogen bond deficiencies equivalent to two
ring systems and four double bonds of 3 were attributed by detailed
spectroscopy. The compound 3 was enclosed a 10-membered cyclic
lactone ring fused to ethyl cyclohexene ring at C-11 and C-6. Ethyl
cyclohexene ring was bonded to methoxyethyl butyl acetate side chain
at C-10 that was attributed by detailed 1H-1H COSY, HSQC and HMBC
assignments. The 13C NMR spectrum in connection with DEPT analyses
displayed the appearance of 23 carbons, including 2 ester carbonyls at δ
172.78 and 173.53, one hydroxylated quarternary carbon at δ 92.06, 4
alkenic carbons between δ 126–131, 5 oxygenated carbons between δ
53–68 and deshielded methyl, methylene and methine carbons between
δ 33-13. The 1H and 13C NMR signals identified characteristic func-
tionalities of oxygenated methylenes {(δH 4.28/δC 59.04); (δH 4.02/δC
63.95); (δH 3.66/δC 66.07); (δH 3.62/δC 68.88)}, methoxy {(δH 3.24,
singlet/δC 53.32)}, and two isolated sp2 disubstituted alkenes {(δH
5.42/δC 131.43; δH 5.41/δC 127.83) and {(δH 5.40/δC 127.71; δH
5.38/δC 126.80)}. The 13C spectrum exhibited one deshielded singlet
carbon resonances at δ 92.06, which proposed that it was located be-
tween oxygen atom and hydroxyl functionality [34]. The absence of
interchangeable hydroxyl in the proton NMR by the deuterium ex-
change (D2O-1H NMR) experiment ascertained the presence of eOH at
δC 92.06. The position of hydroxyl quaternary carbon at C-11 was
confirmed by the HMBC connections from δ 2.35 (H-6), 2.85 (H-10) and
3.66 (H-13) to δ 92.06 (C-11). The 10-membered macrocyclic lactone
enclosed two spin systems based on COSYs, such as δ 3.66 (H-13)/4.28
(H-14) (eOeCH2eCH2eOe) and δ 2.89 (H-3)/5.42 (H-4). This mac-
rocyclic ring was further confirmed by the HMBC connections from δ
2.89 (H-3) to δ 172.78 (C-2), 131.43 (C-4); δ 5.42 (H-4) to δ 172.78 (C-
2), 24.62 (C-3), 127.83 (C-5); δ 2.35 (H-6) to δ 127.83 (C-5); δ 3.66 (H-
13) to δ 59.04 (C-14) and δ 4.28 (H-14) to δ 172.78 (C-2). The spin
systems, such as δ 5.41 (H-5)/2.35 (H-6)/2.06 (H-7)/5.40 (H-8) in-
cluding δ 2.06 (H-7)/1.38 (H-7a)/0.92 (H-7b) suggested the fused at-
tachment of macrocyclic lactone to ethyl cyclohexene ring at C-6. The
fused attachment of macrocyclic lactone and ethyl cyclohexenyl rings
were further assigned by the long-range couplings from δ 2.35 (H-6) to
δ 25.21 (C-7), 22.35 (C-7a), 31.69 (C-10); δ 2.06 (H-7) to δ 127.83 (C-
5), 127.71 (C-8), 126.80 (C-9); δ 1.38 (H-7a) to δ 33.52 (C-6); δ 0.92
(H-7b) to δ 22.35 (C-7a); δ 5.38 (H-9) to δ 127.71 (C-8); δ 2.85 (H-10)
to δ 127.71 (C-8). Another spin system, δ 5.38 (H-9)/2.85 (H-10)/2.45
(H-15) proposed the coupling of acetate side chain at C-10 of ethyl
cyclohexenyl ring system. This was further satisfied with HMBCs from δ
2.43 (H-15) to δ 126.80 (C-9) and 31.69 (C-10). The methoxyethyl
butyl side chain enclosed one spin system from H-17 to H-20 {δ 4.02
(H-17)/2.11 (H-18)/1.60, 1.56 (H-19)/3.62 (H-20)} including H-18/H-
18a/H-18b {δ 2.11 (H-18)/1.36 (H-18a)/1.00 (H-18b)}. These spin
systems were further established by the long-range correlations from δ
4.02 (H-17) to δ 173.53 (C-16), 25.19 (C-19); δ 2.11 (H-18) to δ 68.88
(C-20); δ 1.36 (H-18a) to δ 20.13 (C-18); δ 1.00 (H-18b) to δ 20.13 (C-
18); δ 1.60 (H-19) to δ 29.41 (C-18a); δ 3.62 (H-20) to δ 53.32 (C-21)
and δ 3.24 (H-20) to δ 68.88 (C-20). The lower coupling constants of
5.1 and 5.4 Hz {eCH(4)]CH(5)-} along with 7.3 and 5.2 Hz {eCH
(8)]CH(9)-} suggested the cis-orientation of alkenic groups. The re-
lative stereochemical assignments of chiral protons at C-18, C-10, C-6
and C-7 were recognised by all-inclusive NOE experimentations. NOE
interactions between δ 2.06 (H-7)/2.11 (H-18)/1.56 (Hα-19) appro-
priately recognised their close spatial alignments and their assignments
at equal plane of molecular symmetry, therefore arbitrarily assigned as
α-protons. Therefore, the ethyl chain at C-7 was trans-aligned being
converse to the α-inclined proton at δ 2.06. Moreover, the NOEs were
recorded among δ 2.35 (H-6)/2.85 (H-10)/1.60 (H-19), which in-
dicated their equivalent plane, and the said protons did not find cor-
relations with α-protons (H-7/Hα-19/H-18), and thus, assigned as β-
disposed. The 16-(18-methoxyethyl)butyl acetate moiety at C-10 of
cyclohexenyl ring was laid down opposite to β-inclined proton at δ 2.85
to reduce the steric bulkiness. The IR spectrum registered stretching
bands at 3453, 2926-2855 and 1730 cm−1 that proposed the occur-
rences of hydroxyl, alkanes and carbonyl functionalities, respectively.
The molecular ion at m/z 424 yielded a radical ion at m/z 353. The
latter on elimination of propyl radical recorded a peak at m/z 310,
which on subsequent cleavage of ethyl, methoxy and butyl radicals
yielded m/z 143. The fragment ion at m/z 143 on repeated elimination
of hydroxyl, ethyl and methyl radicals, yielded peaks at m/z 129, 97,
and 87, respectively. The fragment ion at m/z 87 underwent methyl
radical withdrawal, which resulted in m/z 74, which was consistent
with methyl acetate, as the base peak.
The 13-membered macrocyclic lactone derivative, (Z)-12-hydroxy-
14-methyl-4-(pentan-19-yl)-octahydro-benzo [1,15]dioxacyclotridecin-
2-one (4), was isolated from the crude EA-MeOH extract of A. neglectus
by sequential chromatographic purification. Its molecular formula of
C21H34O4 along with its molecular ion at m/z 350 (HRESIMS m/z:
350.2462 [M]+, cal. 350.2457) established the possibilities of five in-
dices of unsaturation corresponding to two cyclic systems and three
double bonds. The studied compound enclosed a 13-membered mac-
rocyclic lactone fused to hydroxy cyclohexene ring at C-9 and C-14. The
macrocyclic ring framework was directly bonded to pentanyl side chain
at C-4, and these designations were attributed by 1H-1H COSY, HSQC
and HMBC analyses. The 13C NMR in conjunction with DEPT experi-
ment ascribed the occurrence of 21 carbons, comprising one each of
ester carbonyl (at δ 172.55) and quaternary carbon at δ 70.51, along
with four alkenes between δ 127–131, two oxygenated methylenes at δ
65.96 and 59.31, one hydroxylated methine at δ 53.38, and deshielded
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carbons between δ 33-13. The D2O exchange-1H NMR experiment
supported the existence of hydroxyl proton at δ 53.38. The 1H/13C NMR
and HSQC resonances identified the characteristic groups corre-
sponding to oxygenated methylene end of ester (δH 4.34, 4.05/δC
59.31); oxygenated methylene (δH 3.73/δC 66.96), hydroxy methine
(δH 3.33, pentet/δC 53.38), one trisubstituted alkene {(δC 131.43; δH
5.41/δC 128.09);> C]CHe}, and one disubstituted alkene {(δH 5.37/
δC 129.00; δH 5.39/δC 127.67); −CH]CHe}. Notably, the previously
reported rearranged 13-membered macrolides was found to be a
benzoate-fused macrocyclic ring [35]. Herein, the titled compound
enclosed 13-membered lactone fused to the cyclohexenyl ring, which
was proposed by the combination of HMBC/1H-1H COSY correlations.
The compound enclosed four spin systems in which three belonged to
pentanyl marolactone ring and one to the cyclohexenyl ring. The
COSYs, such as δ 2.43 (H-3)/1.96 (H-5)/5.37(H-6); δ 5.39 (H-7)/2.88
(H-8) and δ 3.73 (H-16)/4.34, 4.05 (H-17) were accounted for the 13-
membered ring. This macrocyclic ring was attributed by HMBCs from δ
2.43 (H-3) to δ 172.55 (C-2), 25.22 (C-4), 20.14 (C-5); δ 2.11 (H-4) to δ
172.55 (C-2), 129.00 (C-6); δ 1.96 (H-5) to δ 172.55 (C-5); δ 5.37 (H-6)
to δ 25.22 (C-4); δ 2.88 (H-8) to δ 131.43 (C-9) and δ 4.05 (H-17) to δ
172.55 (C-2). Other 1H-1H COSYs at δ 5.41 (H-10)/2.34 (H-11)/3.33
(H-12)/2.04 (H-13) were enclosed in the cyclohexenyl ring. The fused
attachment of hydroxyl cyclohexenyl ring to 13-membered macrocyclic
lactone at C-14 and C-9 were further corroborated by HMBCs from δ
2.34 (H-11) to δ 131.43 (C-9); δ 3.33 (H-12) to δ 70.51 (C-14); δ 2.04
(H-13) to δ 70.51 (C-14); δ 3.73 (H-16) to δ 70.51 (C-14) and δ 4.05 (H-
17) to δ 70.51 (C-14). One singlet methyl {δH 1.31/δC 22.35 (C-18)}
was found to be positioned at C-14, which was assigned on the basis of
HMBC connections from δ 1.31 (H-15) to δ 70.51 (C-14). The assign-
ment of pentanyl side chain and its connection to macrocyclic ring was
proposed by 1H-1H COSY cross-peaks from δ 2.11 (H-4)/1.62 (H-19)/
1.33 (H-20)/0.99 (H-21) including δ 1.62 (H-19)/1.36 (H-22)/0.92 (H-
23). Also, it was further substantiated by the HMBC correlations from δ
1.62 (H-19) to δ 29.01 (C-20), 29.41 (C-22); δ 1.33 (H-20) to δ 13.33
(C-21) and δ 1.36 (H-22) to δ 13.09 (C-23). The lesser coupling con-
stants of 2.9 and 3.8 Hz {eCH(6)]CH(7)e} suggested the cis-orienta-
tion of alkenic groups in the macrocyclic ring system. NOE couplings
between the protons at δ 2.11 (H-4)/4.05 (Hβ-17) recognised their
closer spatial alignments, and therefore, arbitrarily designated as β-
disposed. Thus, the pentanyl chain at C-4 was trans oriented being
opposite to β-disposed proton at δ 2.11. Also, NOEs were recorded
between δ 3.33 (H-12)/4.34 (Hα-17), which indicated their equal mo-
lecular plane of symmetry, and thus, assigned as α-disposed. The hy-
droxyl at C-12 was β-disposed being opposite to the proton at δ 3.33.
The IR spectrum of 4 registered stretching absorptions at 3439, 2925-
2855, 1624, and 1736 cm−1 corresponding to the hydroxyl, alkanes,
alkenes and carbonyl groups, respectively. The molecular ion at m/z
350 yielded m/z 316 through the elimination of methyl and hydroxyl
radicals. The fragment at m/z 267 underwent hydroxyl and repeated
ethyl radical eliminations to form m/z 130 corresponding to C7H14O2
fragment, as the base peak.
3.3. Bioactive properties of macrocyclic lactone derivatives from A.
neglectus
The studied macrocyclic lactones manifested prospective bioactive
properties against various oxidative agents (ABTS+/DPPH%) and ACE-I
that transform Ag-I to Ag-II, an active vasoconstrictor (Table 2). The
macrocyclic derivatives bearing furo [1,4,8]trioxacyclohexadecine-
12,19-dione moiety (2) and substituted 2-oxobenzo [1,12]dioxecin-10-
yl) acetate (3) showed significantly higher (p<0.05) anti-oxidant po-
tential against DPPH% (IC50 0.95 and 0.98mM, respectively) than those
reported by 1 and 4 (IC50 1.34 and 1.73mM respectively), and α-to-
copherol (IC50> 1.26mM). The compound 2 displayed significantly
higher ABTS+ inhibitory activity (p<0.05) than other compounds,
notwithstanding that their bioactivities were significantly higher when
corresponded to α-tocopherol (IC50 1.75mM; p<0.05). The macro-
cyclic derivatives, 2 and 3 exhibited notably higher (p<0.05) anti-
hypertensive properties against ACE-I enzyme (IC50 1.12 and 1.17mM)
proceeded by 1 (IC50 2.43mM) and 4 (IC50 1.85mM), in declining
order.
The anti-oxidant potentials of a macrocyclic lactone metabolite
were previously reported from the Babylonidae gastropod mollusc
Babylonia spirata, and it was found that its molecular descriptors played
significant roles to impart free radical scavenging potential in the bio-
logical system [28]. Additionally the anti-hypertensive bio-potentials of
the metabolites were corroborated with their molecular descriptors
wherein hydrophobicity and electronic variables played considerable
roles towards their bioactivities [13].
The macrocyclic lactone analogues showed hydrophobicity-lipo-
philicity equilibrium within the boundaries of optimum threshold (log
Pow 2.0–3.5) (Table 2). Notably, the hydrophobicity of compounds 2
and 4 were similar, and within the acceptable thresholds (log Pow
3.2–3.3), although the lesser electronic properties of benzo [1,15]di-
oxacyclotridecin-2-one (4, tPSA 55.8; Pl 39.6×10−24 cm3) than those
of the furo [1,4,8]trioxacyclohexadecine-12,19-dione analogue (2,
tPSA 71.1; Pl 43.9×10−24 cm3) might contribute towards higher polar
interaction of latter at the enzyme active site leading to its greater ACE
inhibitory activity. Notably, log Pow of a compound between 2–5 was
contemplated to be optimum in enabling a steady hydrophobicity-li-
pophilicity interaction [36]. The macrocyclic lactone (2) was found to
possess greater numbers of reaction centres, which were implicated by
greater number of ester groups resulting in effective electron delocali-
sation to form keto-enol tautomers through resonance stabilisation. The
latter appeared to assist in relocating the protons to neutralise the
DPPH radical, and subsequently imparted anti-oxidant activity. How-
ever, other functionalities, such as unsaturations and ether moieties
also possessed considerable roles towards increasing the total polar
surface area and polarisability index, which appeared to increase its
target bio-potentials [37]. Notably, the electronic properties of com-
pounds 2 and 3 were greater (tPSA 71–91) as compared to those re-
corded with substituted 7-hydroxy-5-methyl-1, 4-dioxecan-10-one (1,
tPSA 65) and octahydro-benzo [1,15]dioxacyclotridecin-2-one (4, tPSA
56) analogues (Table 2). The steric properties did not appear to con-
tribute important part in bioactivities of the studied compounds. The
higher molecular polarisability (which characterised the electronic
systems) along with balanced hydrophobicity-hydrophilicity coefficient
of compound 2 (log Pow 3.20) disclosed its greater bioactivities com-
pared to other studied compounds [38]. It could be inferred that anti-
oxidative potency of the macrocyclic lactone analogues might poten-
tially inhibit the ACE-I enzyme, and subsequently retard the hy-
pertension-related ailments [39].
3.4. Kinetic properties of ACE-I inhibition
The means of inhibition and inhibition constants (Ki) of macrocyclic
lactone derivatives (compounds 1-4) were determined by Dixon and
Lineweaver-Burk plots. The isolated compounds were deduced to in-
hibit ACE-I in a non-competitive fashion as determined by the
Lineweaver-Burk plot (Fig. S45-S48). This implied that the compounds
were bound at an alternate site from that of the substrate, and thus goes
about as ACE inhibitors by shaping enzyme-substrate-inhibitor or en-
zyme inhibitor edifices that would diminish effectiveness of enzyme
catalysis. The mode of inhibition of ACE activity in the being of studied
compounds was asserted by the decreased apparent Vmax and stable Km
values, which were deduced from the Lineweaver-Burk plot. The in-
verse relation of Vmax with inhibitor (studied macrocyclic lactones, 1-4)
concentrations appropriately recognised the typical character of non-
competitive inhibition [40]. Among the studied compounds, furo
[1,4,8]trioxacyclohexadecine-12,19-dione derivative (2) exhibited
lesser apparent Vmax (0.51-0.14 ΔA/min) than other macrocyclic lac-
tones, which implied that it could efficiently bind with ACE-I to retard
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Table 2
In vitro bioactive potentials (anti-oxidant and anti-hypertensive) and molecular descriptors (electronic, steric and hydrophobic) of compounds 1-4 from A. neglectus.
Bioactivities
Anti-oxidant Activity (IC50; mM) 1 2 3 4
aDPPH scavenging activity 1.73a± 0.05 0.95b±0.04 0.98b± 0.02 1.34c±0.03
aABTS+ scavenging activity 1.50a± 0.04 0.81b±0.02 0.87c± 0.03 1.14d± 0.05
Anti-hypertensive Activity (IC50; mM) 1 2 3 4
aACE-I inhibition activity 2.43a± 0.03 1.12b±0.02 1.17b± 0.03 1.85c±0.04
Molecular Descriptorsb
Electronic
tPSA 64.99 71.06 91.29 55.76
Pl (X10−24 cm3) 32.05 43.90 44.39 39.58
Steric
MR (cm3mol−1) 81.83 113.01 78.14 101.91
MV (cm3) 280.8 401.3 387.42 331.4
Pr (cm3) 706.4 949.95 964.4 836.7
Hydrophobic
Log Pow 2.64 3.2 2.96 3.29
a The bioactivities were expressed as IC50 values (mM). The samples were analyzed in triplicate (n=3) and expressed as mean± standard deviation. Means
followed by different superscripts (a–d) within the same row indicated significant differences (p<0.05).
b tPSA: Topological polar surface area; Pl: polarizability; MR: molar refractivity; MV: molar volume; Pr: parachor; Log Pow: logarithm of octanol-water coefficient.
The molecular descriptors were calculated by using ChemDraw® Ultra (CambridgeSoft Corporation, Cambridge, MA, USA; version 8.0) and ACD ChemSketch
(Advanced Chemistry Development, Inc., Canada; version 12.0) softwares.
Fig. 2. Kinetic studies of the pharmacologic response with regard to mode of inhibition of ACE-I to the studied macrocyclic lactone analogues. Representation of
Dixon plots for compounds 1 through 4 (A-D), for the determination of the inhibition constant Ki. The Ki value was determined from the negative X-axis value at the
point of the intersection of the four lines. The data were expressed as the mean reciprocal of initial velocity for triplicates (n= 3) at each substrate concentration.
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the velocity of the enzyme reaction (Table S2). The Dixon plots of ACE-I
reaction in presence and without metabolites (1-4) at three different
concentrations were displayed in Fig. 2 A-D. The Ki values deduced
from the Dixon plots were directly proportional to the ACE-I inhibition
by isolated macrocyclic lactones. Notably, the compound 2, with lesser
values of the inhibitory constant (Ki= 1.0mM) towards ACE-I, was
found to bind more effectively to the enzyme in a non-competitive
manner, and could describe the greater inhibitory ramificatons than
those displayed by other compounds (Ki> 1.1mM).
3.5. In silico molecular docking analysis of the macrocyclic lactones
The in silico molecular docking analyses of the isolated macrocyclic
lactones (1-4) were performed against ACE-I enzyme, and their RMSD
results were studied (Fig. S49). The hydrogen-bonded amino acyl re-
sidues and free energy between the macrocyclic lactones and ACE-I
active sites were recorded (Table 3). A grid box larger enough to cover
the potential binding site of ACE-I was ascribed with the coordinates,
x= 39.979, y= 37.622, z= 50.808 (56 Å×58 Å×58 Å) [41]. In si-
lico molecular docking analyses of macrocyclic lactones with ACE-I
disclosed that the docked ligands could conceivably bind with target,
and displayed reduced binding energies (−8.03 to −9.84 kcal mol−1).
Particularly, furo [1,4,8]trioxacyclohexadecine-12,19-dione derivative
Table 3
Number of hydrogen bonds (H-bonds), hydrogen bonded (H-bonded) amino
acid residue and corresponding distance (A°), binding energy and inter-
molecular energy between the ligands (compounds 1-4) and the binding sites of
ACE-I.
Ligands aNo. of
H-bonds
bH-bonded amino acid
residues and
corresponding distance
(A°)
bBinding
energy (kcal
mol−1)
bIntermolecular
energy
(kcal mol−1)
1 1 GLY 404.A (3.40) −8.03 −8.93
2 3 HIS 410.A (2.91)
ASP 358.A (2.76)
TYR 394.A (3.39)
−9.84 −10.95
3 3 SER 355.A (2.81)
GLU 411.A (3.39)
ASP 358.A (2.99)
−8.76 −10.84
4 2 HIS 353.A (3.24)
SER 355.A (3.10)
−8.35 −9.25
a Hydrogen bonding interactions between the ligand and the protein com-
plexes.
b Molecular docking simulations were carried out using Autodock 4 software
tool.
Fig. 3. Closer view of molecular binding interactions of compound-2 (A) in the catalytic site of ACE-I as deduced from the molecular docking simulations. The red-
coloured bond indicated the H-bonding interactions and corresponding distance (Å) with the binding site of ACE. (B) A predicted interaction between the macrocyclic
lactone analogue (2) with the enzyme ACE. (C) A representative interaction of the amino acyl residues of ACE-I, which might interact with the macrocyclic lactone
analogue 2 (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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(2) registered least binding energy (−9.84 kcal mol−1), proceeded by
those of compounds, 3 (−8.76 kcal mol−1), 4 (−8.35 kcal mol−1) and
1 (−8.03 kcal mol−1), in increasing order. The binding energy ap-
peared to reflect the ligand interaction with residues as a principal
index to measure inhibitory activity of ligand [41]. The lesser binding
energy of 2 with ACE was deduced to be cogent with its higher ACE-I
inhibitory activity (IC50 1.12mM). The studied compounds 2 and 3
exhibited hydrogen bond interactions with three amino acyl residues
(His 410.A, Asp 358.A, Tyr 394.A and Ser 355.A, Glu 411.A, Asp 358.A,
respectively) (Fig. 3, Fig. S49). The macrocylcic lactone 4 displayed two
hydrogen bonds with two His 353.A and Ser 335.A, whereas 1 exhibited
one hydrogen bond with Gly 404.A (Table 3). Additionally, the titled
ligands (1-4) possessed specific interaction with the molecular receptor
(ACE-I), and were found to be lesser than 3.5 Å, which subsequently
implicated their effective binding property to form ligand-protein
complex [42]. In the current study, the ligand (2) exhibited binding
energy of −9.84 kcal mol−1 with ACE-I protein target that was found to
be comparable with the standard anti-hypertensive agent captopril
displaying a binding affinity of −9.66 kcal mol−1 [42]. The inter-
molecular energy were inferred to be lesser for macrocylic lactones, 2
and 3 (−10.95 and −10.84 kcal mol−1, respectively) compared to
those displayed by 4 (−9.25 kcal mol−1) and 1 (−8.93 kcal mol−1).
The least binding and intermolecular energies of compound 2, thus,
inferred its more prominent ACE-I inhibition activity.
Fig. 4. (A) Microscopic view (20 x magnification) of healthy H9C2 cells (represented as HC) and the average cell area (852 μm2), (B) Ag-II induced cardiac
hypertrophy on H9C2 cells showing degenerated cardiomycetes (DC) due to enlargement, rounding, detachment and membrane blebbing in the H9C2 cells (increased
average cell area to 6916 μm2), (C) compound 2 attenuated Ag-II induced cardiac hypertrophy on H9C2 cells at 6.25 μg mL−1 showing partial regeneration (PRC) of
the hypertrophied cells (decreased average cell area to 6560 μm2), (D-E) partial regeneration of hypertrophied degenerated cardiomycetes at 12.5 μg mL-1 and at
25 μg mL−1 (average cell area of 3695 μm2 and 2324 μm2, respectively), and (F) regenerated hypertrophied (RC) cell (decreased cell area of 913 μm2) at 50 μg mL−1.
The compound 2 was found to regenerate the cardiomycetes.
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3.6. Ex-vivo study of macrocyclic lactone derivative bearing substituted furo
[1,4,8]trioxacyclohexadecine-12,19-dione (2) to inhibit angiotensin-II
induced cardiac hypertrophy on H9C2 cell
Enzyme inhibition kinetic study and molecular docking simulations
displayed that the macrocyclic lactone derivative bearing substituted
furo [1,4,8]trioxacyclohexadecine-12,19-dione (2) possessed potent
ACE-I inhibitory properties compared to other analogues. Hence,
compound 2 was chosen for cytotoxicity studies, and to attenuate Ag-II
prompted cardiac hypertrophy on H9C2 cell. Likewise, the compound 2
did not induce cytotoxicity on H9C2 cells, and at 25 μg mL−1 exhibited
maximum viability (86%).
The inhibitory potential of macrocyclic lactone derivative (2) to
attenuate Ag-II prompted cardiac hypertrophy on H9C2 cell lines re-
cognised that the cells appeared to undergo significant morphologic
changes, when exposed to 100mM of Ag-II for 24 h (Fig. 4). Notably,
angiotensin treatment increased the cell area to 6916.218 ± 584 μm2
when compared to the untreated control samples (852.151 ± 79 μm2)
(Table S3). Enlargement and apoptotic loss of cardiomycytes were the
key pathological changes in cardiac hypertrophy, resulting in tissue
hypoxia and successive loss of cardiomyocytes resulting in heart failure
[43]. In the present study, the enlarged and apoptic cells showed the
cell regeneration after the treatment of macrocyclic lactone derivative
(2) at different concentrations (6.25–50 μg mL−1). Image J analysis
displayed that treatment with compound 2 exhibited a dose-dependent
decrease in cell area suggesting anti-hypertrophic effects. The average
cell area of hypertrophied H9C2 cell lines, upon the induction of the
studied compound at 12.5 μg mL-1 was found to be
3695.594 ± 285 μm2, and 913.354 ± 84 μm2 at 50 μg mL-1 test con-
centrations (Table S3). The ex-vivo studies revealed that compound 2
imparted protective effects against Ag-II induced cardiac hypertrophy
at 25 μg mL−1 on H9C2 cell lines, wherein about 34 percent decrease in
cell area with increase in viability could be attributed to anti-hyper-
trophic effects of the compound administrated. Therefore, the com-
pound 2 was found to regenerate the cardiomycetes. A significant re-
duction of about 86.8% in cellular size of the hypertrophied H9C2 cell
lines upon treatment of the macrocyclic lactone derivative bearing furo
[1,4,8]trioxacyclohexadecine-12,19-dione moiety (2) appropriately
recognized the potential of the studied compound to attenuate Ag-II
induced cardiac hypertrophy. The decrease in the cellular size of the
hypertrophied H9C2 cell lines, upon the induction of the protective
agent, is the principal factor, which could be considered for the anti-
hypertensive properties [44]. It is of note that elevated levels of reactive
oxidative species appeared to impede cardiomyocyte functionality by
impairing the ion channels that could damage the structural coherence
of ion channels [45]. Since reactive oxidative species act as signaling
molecules to develop cardiac hypertrophy, agents that occlude the
generation of reactive oxidative species would have medicinal sig-
nificance against cardiovascular ailments.
4. Conclusions
ACE, a multifunctional enzyme has been considered as an im-
perative constituent of renin-angiotensin framework to biosynthesise
Ag-II, an active vasoconstrictor to induce hypertension and other re-
lated disorders. Inhibition of ACE is considered to be an important
therapeutic approach in the treatment of hypertension. Marine-derived
bioactive compounds are seeking immense attention in the treatment of
Ag-II induced cardiac hypertrophy, and the current study reported four
hitherto undescribed macrocyclic analogues from the organic extract of
A. neglectus with inhibitory properties against ACE. Among the studied
oxygenated macrocyclic lactones, the one bearing substituted furo
[1,4,8]trioxacyclohexadecine-12,19-dione moiety (2) possessed potent
ACE-inhibitory properties compared to other analogues. Therefore, it
was chosen for cytotoxicity studies, and to attenuate Ag-II prompted
cardiac hypertrophy on the H9C2 cell. The ex vivo studies also
implicated that compound (2) significantly inhibited Ag-II induced
cardiac hypertrophy on H9C2 cell, and therefore, could be utilised to
develop potential pharmacophore lead against hypertension and re-
lated ailments. Owing to their potential bioactive properties, an ap-
proach to develop synthetic macrocyclic lactone leads for use against
hypertensive-related disorders could be anticipated.
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